M. Kidd
Internal medicineSurrogate endpointOncologyMcNemar's testNeuroendocrine tumorsDiseaseLiquid biopsyLanreotide AutogelClinical efficacyOctreotide larMedicineCohortBiomarker (medicine)Chromogranin AGastroenterology
Publications 2
#1I.M. Modlin (Yale University)
Last. Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
view all 11 authors...
Background null Biomarkers are key tools in cancer management. In neuroendocrine tumors (NETs), Chromogranin A (CgA) was considered acceptable as a biomarker. We compared the clinical efficacy of a multigenomic blood biomarker (NETest) to CgA over a 5-year period. null null null Patients and methods null An observational, prospective, cross-sectional, multicenter, multinational, comparative cohort assessment. Cohort 1: NETest evaluation in NETs (n = 1684) and cancers, benign diseases, controls (...
#2Anna LewczukH-Index: 9
Last. Jarosław B. ĆwikłaH-Index: 23
view all 9 authors...